Loading
Life sciences · Journal article
Bioactive Materials · August 4, 2026
Encouraging direction, but not yet definitive.
This preclinical study demonstrates that EGFR activity declines in skeletal stem/progenitor cells with aging in mice and that loss of EGFR function impairs fracture healing, while EGFR overactivation via HBEGF or HBEGF-releasing hydrogel accelerates healing. The work provides mechanistic insight into age-related fracture delayed union and a potential therapeutic target, but remains at the preclinical stage and does not yet establish clinical efficacy or safety.
Preclinical mechanistic and intervention study in genetically modified and wild-type aged mice. Aged mice; specific age, sex, and number per group not stated in excerpt.. Intervention: Stem/progenitor-specific EGFR overactivation via HBEGF overexpression or injectable self-healing adhesive HBEGF@HADA hydrogel. Compared with: Egfr iCKO (loss-of-function) model and age-matched wild-type controls; specific comparator arms not fully detailed in excerpt.. China (Wuhan and Zhengzhou).
EGFR activity in skeletal stem/progenitor cells decreased as mice aged, resulting in delayed fracture healing Egfr iCKO mice (stem/progenitor-specific EGFR inactivation) developed obvious delayed fracture healing Prx1-Cre HBEGF-overexpressing aged mice exhibited accelerated fracture healing with promotion of osteogenesis and angiogenic coupling and inhibition of cellular senescence
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work identifies EGFR signaling as a therapeutic target for age-related fracture delayed union and presents a hydrogel delivery strategy. However, the findings are preclinical and do not yet establish efficacy or safety in humans; clinical translation would require further development and human trials.
Sound mechanistic study in aged mice using genetic models and a novel hydrogel intervention showing accelerated fracture healing, but limited to preclinical animal work without human efficacy data or clinical trial evidence.
As stated by the source record.
This work identifies EGFR signaling as a therapeutic target for age-related fracture delayed union and presents a hydrogel delivery strategy. However, the findings are preclinical and do not yet establish efficacy or safety in humans; clinical translation would require further development and human trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The cellular and molecular events responsible for fracture healing becoming delayed with aging remain unclear. Epidermal growth factor receptor (EGFR) signaling has been reported to play a critical role in bone regeneration. However, knowledge of its specific function in skeletal stem cells during aging-induced fracture delayed union remains scant. In the present study, we first demonstrated that EGFR activity in skeletal stem/progenitor cells decreased as mice aged and thus resulted in delayed fracture healing. To further investigate whether the EGFR signaling can be targeted as a potential therapy for aging-induced fracture delayed union, we designed a two-pronged approach: one involved crossing Prx1-Cre with Egfr flox/flox mice to generate a model with stem/progenitor-specific EGFR inactivation (Egfr iCKO), while the other entailed overexpressing heparin-binding EGF-like growth factor (HBEGF), an EGFR ligand, to generate a stem/progenitor-specific EGFR overactivation model. Our findings revealed that Egfr iCKO mice developed obvious delayed fracture healing. Conversely, Prx1-Cre HBEGF-overexpressing aged mice exhibited accelerated fracture healing due to promotion of osteogenesis and angiogenic coupling, as well as inhibition of cellular senescence. Based on these results, we developed an injectable, self-healing, adhesive hydrogel, which sustainably released HBEGF in situ at the fracture site. This hydrogel effectively promoted cartilage-to-bone transition as well as the fracture healing process in aged mice. Together, our findings demonstrate that EGFR signaling is a molecular mechanism involved in healing fractures in the elderly and provide a promising therapy to target EGFR signaling for the treatment of fracture delayed union caused by aging.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.